RA Capital Management
9 rounds tracked since 8 January 2026.
- Rounds
- 9
- Led
- 5
- Capital in these rounds
- $1.4B
Sectors
Countries
Rounds
- Solstice OncologyLeadDevelops immunotherapies for earlier treatment of cancer $225MSeries A · 9 Sept
- Superluminal MedicinesDevelops small-molecule medicines targeting GPCRs and metabolic diseases $60MSeries B · 3 Sept
- Typewriter TherapeuticsLeadDevelops non-viral genetic medicines for cancer, autoimmune diseases, and severe genetic disorders. $56MSeries A · 2 Sept
- Celea TherapeuticsDevelops treatments for people with serious respiratory diseases, starting with deupirfenidone for idiopathic pulmonary fibrosis. $180M2 Jul
- Ollin BiosciencesDevelops OLN324 therapy for diabetic macular edema and wet age-related macular degeneration. $330MSeries B · 24 Jun
- Adcendo ApSDevelops antibody-drug conjugate cancer therapies through a clinical-stage pipeline. $75MSeries C · 14 Apr
- ILiAD BiotechnologiesLeadDevelops vaccines, including the BPZE1 pertussis vaccine candidate. $115MSeries B · 10 Feb
- Kinaset TherapeuticsLeadDevelops a novel inhaled therapeutic candidate for respiratory diseases. $103MSeries B · 10 Jan
- Parabilis MedicinesLeadDevelops oncology therapies, including FOG-001 (zolucatetide), using its Helicon platform. $305M8 Jan
Often invests with
The Daily Raise
The day's rounds in your inbox each morning.
Subscribe to The Daily Raise